NFSG
MBRX icon

Newbridge Financial Services Group’s Moleculin Biotech MBRX Stock Holding History

Newbridge Financial Services Group’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318 Hold
114
– – ﹤0.01% 1170
2026
Q1 		$261 Hold
114
– – ﹤0.01% 1122
2025
Q4 		$377 Sell
114
-1
-0.9% -$9 ﹤0.01% 1121
2025
Q3 		$1.52K Hold
115
– – ﹤0.01% 1156
2025
Q2 		$866 Buy
115
+60
+109% +$1.23K ﹤0.01% 1214
2025
Q1 		$1.33K Hold
55
– – ﹤0.01% 924
2024
Q4 		$2.32K Hold
55
– – ﹤0.01% 952
2024
Q3 		$3.88K Hold
55
– – ﹤0.01% 524
2024
Q2 		$4.81K Buy
55
+28
+104% +$3.23K ﹤0.01% 853
2024
Q1 		$4.05K Buy
+27
New +$5.76K ﹤0.01% 915

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newbridge Financial Services Group's MBRX Position: Q2 2026 in Review

Newbridge Financial Services Group held its Moleculin Biotech (MBRX) position steady in Q2 2026 at 114 shares worth $318. The position accounts for ﹤0.01% of the portfolio, ranked #1170.

Newbridge Financial Services Group first reported a position in MBRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.81K in Q2 2024. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Newbridge Financial Services Group held 114 shares of Moleculin Biotech worth $318 as of Q2 2026.
  • Newbridge Financial Services Group left its Moleculin Biotech share count unchanged in Q2 2026.
  • Moleculin Biotech made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1170 holding.
  • Newbridge Financial Services Group first reported a position in Moleculin Biotech in Q1 2024 and has held it in 10 quarters since.
  • Newbridge Financial Services Group's Moleculin Biotech position peaked at $4.81K in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.